Your search history is turned on.
Date: November 8, 2022 Jurisdictions: All jurisdictions
Microsoft Word - Zymeworks-110822.htm Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks lead clinical candidate, for total potential payments of up to $1.76 billion, plus royalties on net sales Hosted Ear...
Date: October 25, 2022 Jurisdictions: All jurisdictions
013 1 \SIA CCA.N.IN1511% \I SR RE.GiSIg\( 14 As la1 SUPREME COURT OF BRITISH COLUMBIA No. S226843 Vancouver Registry I N THE MATTER OF SECTION 288 OF THE BUSINESS CORPORATIONS ACT, S.B.C. 2002, CHAPTER 57, AS AMENDED AND IN THE MATTER OF A PROPOSED ARRANGEMENT INVOLVING ZYMEWORKS INC., ZYMEWORKS DELAWARE INC., ZYMEWORKS CALLCO U...
Date: October 21, 2022 Jurisdictions: All jurisdictions
printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 Zymeworks BC Inc. (Exact name of registrant as specified in its c...
Date: October 20, 2022 Jurisdictions: All jurisdictions
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms Program beginning today at 8:30 AM Eastern Standard ...
Date: October 19, 2022 Jurisdictions: All jurisdictions
printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Zymeworks BC Inc. (Exact name of registrant as specified in its c...
Microsoft Word - Zymeworks-101922.htm Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab Jazz Pharmaceuticals to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment of $325 million, at Jazzs option, ...
Date: October 18, 2022 Jurisdictions: All jurisdictions
printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 Zymeworks BC Inc. (Exact name of registrant as specified in its c...
Zymeworks to Host Third Quarter Results Conference Call Zymeworks to Host Third Quarter Results Conference Call VANCOUVER, British Columbia--(BUSINESS WIRE)--October 18, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its third quarter 2022 f...
Date: October 13, 2022 Jurisdictions: All jurisdictions
NOTICE OF CHANGE IN CORPORATE STRUCTURE (PURSUANT TO SECTION 4.9 OF NATIONAL INSTRUMENT 51-102 CONTINUOUS DISCLOSURE OBLIGATIONS) 1. Names of Parties to the Transaction: Zymeworks Inc., a Delaware corporation formerly known as Zymeworks Delaware Inc. (the Company); Zymeworks BC Inc., a corporation existing under the laws of the Province of British Col...
Microsoft Word - 268632_Zymeworks_MCR_SEDAR.docx FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Zymeworks Inc. (Company) 114 East 4th Avenue - Suite 800 Vancouver, BC, Canada V5T 1G4 Item 2: Date of Material Change October 13, 2022 Item 3: News Release A news release announcing the material change was...